Infertility
Conditions
Brief summary
AME is a non-interventional, prospective, longitudinal and multicenter study. This study aims to measure the relationship between antimüllerian hormone serum level (AMH), as measured by a fully automated assay and the initial dose of Menopur® HP-hMG 600 IU/mL prescribed for infertile women undergoing their first IVF/ICSI cycle in the current practice.
Interventions
DRUGMenotrophin
Sponsors
Ferring Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
No
Inclusion criteria
* Women aged between \[18-42\] years. * Both ovaries present. * Regular menstrual cycles presumed to be ovulatory. * Primary or secondary infertility of any origin for more than 12 months. * Patient with at least one result of antimüllerian hormone (AMH) measured by a fully automated assay available before inclusion, and performed in the past 12 months before inclusion. * Candidates eligible to a first IVF/ICSI cycle and for whom Menopur® HP-hMG 600 IU/mL has been prescribed. * Having received oral and written information on the study, without any objections for the use of his/her anonymized data, and having signed a written Informed Consent Form.
Exclusion criteria
* Major uterine or ovarian morphological abnormalities or past ovarian surgery. * Endometriosis stage III/IV. * Polycystic ovarian syndrome. * Major endocrine or metabolic abnormalities without treatment. * Patient included in an interventional study assessing treatment for infertility.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Spearman correlation coefficient between Menopur® 600 IU/mL dose and AMH serum levels | At baseline (inclusion) |
Countries
France
Outcome results
None listed